Table 1.

Summary of demographic and clinical data of patients treated depending on generation of TKI received

	1st/2nd generation TKI (n = 60)	3rd generation TKI (n = 90)
Age at diagnosis (median, SD)	61.5 (13.2)	66 (11.7)
Age at TKI initiation (median, SD)	62.4 (20.3)	67.1 (12.3)
Sex (n)	Male: 21 Female: 39	Male: 28 Female: 58
Ethnicity (n)	Hispanic: 17 Asian/Pacific Islander: 28 Black: 1 White: 13 Unknown/other: 1	Hispanic: 14 Asian/Pacific Islander: 45 Black: 4 White: 18 Unknown/other: 5
Smoking status (n)	Never smoker: 47 Ever smoker: 13	Never smoker: 64 Ever smoker: 22
Tumor histology (n)	Adenocarcinoma: 56 Squamous: 1 Adenosquamous: 2 NOS: 1	Adenocarcinoma: 80 Squamous: 2 Adenosquamous: 3 NOS: 1
Initial EGFR TKI (n)	Erlotinib: 40 Afatinib: 18 Gefitinib: 2	Osimertinib: 86
EGFR mutation/s (n)	Exon 19 ins/del: 31 L858R: 15 “Rare” Mutation: 8 “Compound” Mutation: 2 Unknown/Data not accessible: 4	Exon 19 ins/del: 45 L858R: 33 “Rare” Mutation: 4 “Compound” Mutation: 4 Unknown/Data not accessible: 0
Cancer stage at TKI initiation (n)	Stage 1: 0 Stage 2: 1 Stage 3: 2 Stage 4: 57	Stage 1: 3 Stage 2: 4 Stage 3: 2 Stage 4: 77
Brain mets at TKI initiation? (n)	No brain mets: 36  + brain mets: 24	No brain mets: 59  + brain mets: 27
Line of therapy (n)	1st line: 51 2nd line or greater: 9	1st line: 76 2nd line or greater: 10
BMI at TKI initiation (n)	< 21: 15  ≥ 21: 36 Data unavailable: 9	< 21: 16  ≥ 21: 67 Data unavailable: 3
NLR at TKI initiation (n)	NLR < 5: 29 NLR ≥ 5: 28 Data unavailable: 13	NLR < 5: 43 NLR ≥ 5: 33 Data unavailable: 10
PLR at TKI initiation (n)	PLR < 180: 18 PLR ≥ 180: 29 Data unavailable: 13	PLR < 180: 34 PLR ≥ 180: 42 Data unavailable: 10
Albumin at TKI initiation (n)	Albumin < 3.2: 6 Albumin ≥ 3.2: 40 Data unavailable: 14	Albumin < 3.2: 6 Albumin ≥ 3.2: 64 Data unavailable: 16